Abstract | BACKGROUND: Agents capable of increasing radioiodine concentration by stimulating the sodium/iodide symporter (NIS) expression have been extensively investigated for the treatment of certain well-differentiated breast cancers. AIM: METHODS: MCF-7, T-47D, MDA-MB231, and HCC-1937 (the latter carrying the BRCA-1 mutation) were exposed to different stimulators and the levels of NIS and LPO mRNA measured by a quantitative RT-PCR. RESULTS: CONCLUSIONS: These data indicate that retinoic acid, alone or in combination with DEX, as well as HDAC-inhibitors are very promising agents for a radioiodine- based therapy in a large spectrum of breast cancers, including neoplasms from both basal and ductal cells, especially for the well-differentiated estrogen-dependent tumors. Other molecules or other drug combinations should be tested to extend the same strategy to the less differentiated and more aggressive tumor cells, including those carrying the BRCA mutation.
|
Authors | M Sponziello, A Scipioni, C Durante, A Verrienti, M Maranghi, L Giacomelli, E Ferretti, M Celano, S Filetti, D Russo |
Journal | Journal of endocrinological investigation
(J Endocrinol Invest)
Vol. 33
Issue 1
Pg. 2-6
(Jan 2010)
ISSN: 1720-8386 [Electronic] Italy |
PMID | 19794300
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Butyrates
- Histone Deacetylase Inhibitors
- Hydroxamic Acids
- RNA, Messenger
- Symporters
- trichostatin A
- sodium-iodide symporter
- Tretinoin
- Dexamethasone
- Lactoperoxidase
|
Topics |
- Breast Neoplasms
(metabolism)
- Butyrates
(pharmacology)
- Cell Line, Tumor
- Dexamethasone
(pharmacology)
- Histone Deacetylase Inhibitors
(pharmacology)
- Humans
- Hydroxamic Acids
(pharmacology)
- Lactoperoxidase
(biosynthesis, genetics)
- RNA, Messenger
(metabolism)
- Symporters
(biosynthesis, genetics)
- Tretinoin
(pharmacology)
|